Jump to content

Ajinomoto Integrates R&D Sites in Japan and Korea with Genedata Bioprocess

Leading Japanese biopharma company expands enterprise-level deployment of Genedata Bioprocess to automate workflows and increase operational efficiency within and between their R&D sites

June 5, 2023
Basel, Switzerland and Tokyo, Japan

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, and Ajinomoto, a leading multinational supplier of cell culture media as well as development and manufacturing services (CDMO), today announced that Ajinomoto has successfully rolled out Genedata Bioprocess® to its Korean sites, Ajinomoto Genexine, in line with Ajinomoto’s transformational R&D digitalization strategy.

“Genedata Bioprocess has been quickly adopted by our Japanese teams to streamline and accelerate our media development activities,” said Hiroyuki Mise, General Manager of Biopharma Solutions Group, Amino Acids Department of Ajinomoto. “The platform integrates with our existing laboratory instrumentation, allowing us to evaluate huge volumes of cell culture media development data at a level of complexity that was previously unimaginable. After the successful deployment in Japan, we have now expanded the use of Genedata Bioprocess to our Korea-based teams to facilitate cross-site projects, resulting in significantly more efficient operations in our joint projects. At the same time, we are preparing for further expansion to our development site in China. Genedata allows us to accelerate cell culture media development so that our biopharma partners can develop novel innovative treatments and vaccines faster and at a lower cost.”

Ajinomoto uses Genedata Bioprocess as their central data backbone to streamline cell culture media development and production operations, including in regulated environments. A chemically defined cell culture medium typically contains dozens of components, the exact amounts of which must be precisely evaluated to improve expression yields and quality of biotherapeutic drugs. Media optimization is essential for the efficient production of modern biological medicines, for example immunotherapies, vaccines, stem cells, and other therapeutics. Defined cell culture media are extremely complex to develop and manufacture, with strict requirements to ensure product quality. Ajinomoto Genexine is known for their flagship products CELLiST™, high-performance media that are chemically defined and free from any animal-derived ingredients.

Genedata Bioprocess is a purpose-built digital platform enabling the end-to-end tracking and analysis of complex cell culture media compositions, including process parameters such as cell growth, together with product analytics and quality data. All information across Ajinomoto’s groups in Korea and Japan can now be traced and related in one central platform that ensures data integrity and compliance. Genedata Bioprocess is an integral part of Ajinomoto’s digitalization strategy, which utilizes automation, AI/ML, and Genedata’s advanced data infrastructure to maximize business value for custom media development projects and CDMO services.

“I am delighted to see that Ajinomoto is expanding the usage of Genedata Bioprocess across its Asian development and manufacturing sites, which is how we envision our platform to be used,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Since the Genedata Biopharma Platform is built on a scalable architecture, it is easy to distribute the management and analysis of big data across multiple sites and set ups. Our mission at Genedata is to accelerate biopharma R&D, and this is a great example of what can be achieved as the industry transitions to biopharma 4.0.”

About Ajinomoto

The Ajinomoto Group, unlocking the power of amino acids, aims to resolve food and health issues associated with dietary habits and aging, and contribute to greater wellness for people worldwide. Based on the corporate message “Eat Well, Live Well.”, we have been scientifically pursuing the possibilities of amino acids to aim for future growth by creating new value through sustainable and innovative solutions for communities and society. The Ajinomoto Group has offices in 36 countries and regions, and sells products in more than 130 countries and regions. In fiscal 2021, sales were 1.1493 trillion yen (9.6 billion U.S. dollars).

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube


Allison Kurz
Public Relations


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

After the successful deployment in Japan, we have now expanded the use of Genedata Bioprocess to our Korea-based teams to facilitate cross-site projects, resulting in significantly more efficient operations in our joint projects.


Hiroyuki Mise
General Manager of Biopharma Solutions Group